Gilead ex­ecs flag tri­al fail­ures for Sjö­gren’s and lu­pus drugs — while swap­ping out a fa­vorite HIV pro­gram of top an­a­lyst

There’s more bad news on the Sjö­gren’s dis­ease front to­day, af­ter Gilead ex­ecs ac­knowl­edged in their Q3 call with an­a­lysts that their trio of drugs — in­clud­ing their top pipeline drug fil­go­tinib — had failed mid-stage tests.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER